Company: AZN
Filing Date: 2025-12-16
Form Type: 6-K
Source: 0001654954-25-013974
Chunk: 8

Company: ASTRAZENECA PLC
Filing Date: 2025-12-16
Form: 6-K
Chunk 8
---
.gov. Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis (IRIS). Available at: https://www.clinicaltrials.gov/ct2/show/NCT05138133 . [Last accessed: December 2025].

#### Matthew Bowden

#### Company Secretary

#### AstraZeneca PLC
<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| AstraZeneca 
 PLC         |

Date:16 December 2025

| By: /s/           
 Matthew Bowden    |
| Name:             
 Matthew Bowden    |
| Title:            
 Company Secretary |